IP Library Granted Patent US 10,793,892
Granted Patent B2
US 10,793,892 · App. 14/358,839 · Granted Oct 6, 2020

Method for detecting the presence of expanded spectrum β-lactamase-producing bacteria in a sample

Inventors: Patrice Nordmann (Le Kremlin Bicetre, FR); Laurent Dortet (Le Kremlin Bicetre, FR); Laurent Poirel (Le Kremlin Bicetre, FR)
Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); UNIVERSITÉ PARIS-SACLAY; ASSISTANTE PUBLIQUE HOPITAUX DE PARIS (APHP)
C12Q1/34C12Q1/00C12Q1/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,793,892
App. No.
14/358,839
Granted
Oct 6, 2020
Kind
B2
Abstract

The present invention relates to a method for detecting the presence of expanded-spectrum ß-lactamase (ß-lactamase hydrolyzing expanded-spectrum cephalosporin)-producing bacteria in a sample, said method comprising the steps of: a) performing cell lysis on a test sample in order to obtain an enzymatic suspension; b) reacting a fraction of the enzymatic suspension obtained in step a) with a reagent kit, said reagent kit comprising —expanded-spectrum ß-lactamase substrate selected from the group consisting of cephalosporins, aztreonam, and cephamycins, —a pH color indicator which will change color when the pH of the reaction mixture is comprised between 6.4 and 8.4, wherein a color change after step b) indicates the presence of expanded-spectrum ß-lactamase-producing bacteria in the test sample. The invention also relates to a reagent kit, to a microtiter plate and to their uses in detecting the presence of expanded-spectrum ß-lactamase producers in a test sample.

Claims (16)

1. A method for detecting the presence of expanded-spectrum ß-lactamase-producing bacteria in a blood or urine sample, said method comprising the steps of:

a) performing cell lysis on the blood or urine sample in order to obtain an enzymatic suspension, wherein said bacteria in said blood or urine sample are not cultured to isolate said bacteria prior to step a);

b) reacting a fraction of the enzymatic suspension obtained in step a) with a reagent kit, said reagent kit comprising

an expanded-spectrum ß-lactamase (EBSL) substrate selected from cephalosporins and aztreonam; and,

a pH color indicator which will change color when the pH of the reaction mixture is from 6.4 and 8.4,

wherein a color change visually observed within 5 minutes to 120 minutes after the beginning of step b) indicates the presence of expanded-spectrum ß-lactamase-producing bacteria in the blood or urine sample.

2. The method according to claim 1 , wherein the expanded-spectrum ß-lactamase-producing bacteria are selected from the group consisting of Acinetobacter, Aeromonas, Bacillus, Bacteroides, Citrobacter, Enterobacter, Escherichia, Klebsiella, Morganella, Pandoreae, Proteus, Providencia, Pseudomonas, Ralstonia, Raoultella, Salmonella, Serratia, Shewanella, Shigella and Stenotrophomonas.

3. The method according to claim 1 , wherein reaction in step b) is carried out at a temperature between 15° C. and 40° C.

4. A method according to claim 1 ,

wherein the ESBL substrate is cefotaxime,

wherein the pH color indicator is phenol red, and

wherein the color change is from red to yellow.

5. The method according to claim 1 , wherein reaction in step b) is carried out at a temperature between 20° C. and 37° C.

6. The method according to claim 1 , wherein the reaction in step b) is carried out over a period of time sufficient to observe a color change.

7. The method according to claim 1 , wherein the reaction in step b) is carried out over a period of time between 20 minutes and 40 minutes.

8. The method according to claim 1 , wherein the expanded-spectrum ß-lactamase substrate which is a cephalosporin or an aztreonam is selected from the group consisting of cefotaxime, ceftriaxone, ceftazidime, cefepime, and cefpirome.

Assignments (2)
MERGER Recorded Aug 28, 2020
From: UNIVERSITE PARIS-SUD XI; COMMUNITY OF UNIVERSITIES AND INSTUTIONS (COMUE)
To: UNIVERSITÉ PARIS-SACLAY
Reel/Frame 053626/0399 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2014
From: NORDMANN, PATRICE; DORTET, LAURENT; POIREL, LAURENT
To: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); UNIVERSITE PARIS-SUD XI; ASSISTANTE PUBLIQUE HOPITAUX DE PARIS (APHP)
Reel/Frame 033538/0336 →
Priority Claims (1)
EP 11306516 · Nov 18, 2011 · regional
Continuity (1)
Related Publication 20140308693A1 · Oct 16, 2014